股本结构
单位：万股
| 公告日期 | 2022-08-09 | 2022-08-09 | 2022-06-27 | 2022-05-10 | 2022-05-10 | 2022-03-30 |
|---|---|---|---|---|---|---|
| 证券总股本 | 16836.48 | 16836.50 | 16832.95 | 16487.45 | 16486.80 | 16479.05 |
| 普通股本 | 16836.48 | 16836.50 | 16832.95 | 16487.45 | 16486.80 | 16479.05 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 33.80 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2022-08-05 | 2022-06-30 | 2022-06-24 | 2022-05-04 | 2022-03-31 | 2022-03-01 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2022-08-09 | 16836.48 | 未披露 | 定期报告 | 2022-08-05 |
| 2022-08-09 | 16836.50 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock in connection with the conversion of series A convertible preferred stock
Vesting of restricted stock units
Issuance of shares of common stock in lieu of board fees
|
2022-06-30 |
| 2022-06-27 | 16832.95 | 未披露 | 定期报告 | 2022-06-24 |
| 2022-05-10 | 16487.45 | 未披露 | 定期报告 | 2022-05-04 |
| 2022-05-10 | 16486.80 | 33.80 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common stock (net of commissions and offering costs of $507)
Vesting of restricted stock units
Issuance of shares under employee stock purchase plan
Issuance of shares of common stock in lieu of board fees
|
2022-03-31 |
| 2022-03-30 | 16479.05 | 未披露 | 定期报告 | 2022-03-01 |
| 2022-03-01 | 16448.20 | 未披露 | 定期报告 | 2022-02-24 |
| 2022-01-31 | 16276.42 | 未披露 |
更多>>
1.Common stock offered by Epizyme 56,666,667 shares.
2.The number of shares of common stock to be outstanding after this offering is based on the 106,097,528 shares of common stock outstanding as of December 31, 2021
|
2022-01-31 |
| 2022-03-01 | 10609.75 | 33.80 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock (net of commissions and offering costs of $515)
Exercise of stock options and vesting of restricted stock units
Issuance of shares of common stock in lieu of board fees
Issuance of shares under employee stock purchase plan
|
2021-12-31 |
| 2021-11-09 | 10389.50 | 未披露 | 定期报告 | 2021-11-04 |
| 2021-11-09 | 10366.20 | 33.80 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock (net of commissions and offering costs of $217)
Issuance of shares under employee stock purchase plan
Issuance of shares of common stock in lieu of board fees
|
2021-09-30 |
| 2021-08-09 | 10224.95 | 未披露 | 定期报告 | 2021-08-04 |
| 2021-08-09 | 10225.00 | 33.80 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock (net of commissions and offering costs of $49)
Exercise of stock options and vesting of restricted stock units
Issuance of shares of common stock in lieu of board fees
|
2021-06-30 |
| 2021-05-06 | 10197.56 | 33.78 | 定期报告 | 2021-04-30 |
| 2021-04-29 | 10197.56 | 未披露 | 定期报告 | 2021-04-16 |
| 2021-05-06 | 10196.88 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Exercise of stock options and vesting of restricted stock units
Issuance of shares under employee stock purchase plan
Issuance of shares of common stock in lieu of board fees
|
2021-03-31 |
| 2021-02-23 | 10178.52 | 未披露 | 定期报告 | 2021-02-18 |
| 2021-02-23 | 10162.70 | 33.80 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common stock in connection with the exercise of the Put Option (net of financing costs of $85)
Issuance of common stock in connection with the conversion of series A convertible preferred stock
Exercise of stock options and vesting of restricted stock units
Issuance of shares of common stock in lieu of board fees
Issuance of shares under employee stock purchase plan
|
2020-12-31 |
| 2020-11-06 | 10158.14 | 未披露 | 定期报告 | 2020-10-30 |
| 2020-11-06 | 10157.60 | 33.80 |
更多>>
From June 30, 2020 to September 30, 2020
Exercise of stock options and vesting of restricted stock units
Issuance of shares under employee stock purchase plan
Issuance of shares of common stock in lieu of board fees
|
2020-09-30 |
| 2020-08-04 | 10147.83 | 未披露 | 定期报告 | 2020-07-30 |
| 2020-08-04 | 10146.40 | 33.80 |
更多>>
From March 31, 2020 to June 30, 2020
Exercise of stock options and vesting of restricted stock units
Issuance of shares of common stock in lieu of board fees
|
2020-06-30 |
| 2020-05-04 | 10106.12 | 未披露 | 定期报告 | 2020-04-30 |
| 2020-04-17 | 10104.96 | 未披露 | 定期报告 | 2020-04-07 |
| 2020-05-04 | 10104.70 | 33.80 |
更多>>
From December 31, 2019 to March 31, 2020
Issuance of common stock in connection with the exercise of the put option (net of financing costs of $85)
Issuance of common stock in connection with the conversion of series A convertible preferred stock
Exercise of stock options and vesting of restricted stock units
Issuance of shares under employee stock purchase plan
Issuance of shares of common stock in lieu of board fees
|
2020-03-31 |
| 2020-02-27 | 10077.14 | 未披露 | 定期报告 | 2020-02-19 |
| 2020-02-27 | 9778.30 | 35.00 |
更多>>
from December 31, 2018 to December 31, 2019
Issuance of common stock (net of commissions and offering costs of $284)
Issuance of common stock to Royalty Pharma (net of commissions and offering costs of $304)
Exercise of stock options and vesting of restricted stock units
Issuance of shares of common stock in lieu of board fees
Issuance of shares under employee stock purchase plan
Issuance of series A convertible preferred stock, net of commissions and beneficial conversion charge
|
2019-12-31 |
| 2019-10-31 | 9107.39 | 未披露 | 定期报告 | 2019-10-25 |
| 2019-10-31 | 9106.90 | 35.00 |
更多>>
from June 30, 2019 to September 30, 2019
Exercise of stock options and vesting of restricted stock units
Issuance of shares under employee stock purchase plan
Issuance of shares of common stock in lieu of board fees
|
2019-09-30 |
| 2019-08-09 | 9103.66 | 未披露 | 定期报告 | 2019-07-31 |
| 2019-08-09 | 9101.60 | 35.00 |
更多>>
From March 31, 2019 to June 30, 2019
Exercise of stock options and vesting of restricted stock units
Issuance of shares of common stock in lieu of board fees
|
2019-06-30 |
| 2019-05-06 | 9083.31 | 未披露 | 定期报告 | 2019-04-30 |
| 2019-04-18 | 9081.10 | 未披露 | 定期报告 | 2019-04-05 |
| 2019-05-06 | 9080.31 | 35.00 |
更多>>
from December 31, 2018 to March 31, 2019
Issuance of common stock (net of commissions and offering costs of $284)
Exercise of stock options and vesting of restricted stock units
Issuance of shares under employee stock purchase plan
Issuance of Series A Convertible Preferred Stock, net of commissions and beneficial conversion charge
|
2019-03-31 |
| 2019-02-26 | 7920.67 | 未披露 | 定期报告 | 2019-02-19 |
| 2019-02-26 | 7917.50 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of common stock (net of commissions and offering costs of $260)
Exercise of stock options and vesting of restricted stock units
Issuance of shares under employee stock purchase plan
Stock in lieu of board fees
|
2018-12-31 |
| 2018-11-02 | 7916.81 | 未披露 | 定期报告 | 2018-10-31 |
| 2018-11-02 | 6957.60 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-08-02 | 6950.31 | 未披露 | 定期报告 | 2018-07-30 |
| 2018-08-02 | 6930.20 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-08 | 6948.78 | 未披露 | 定期报告 | 2018-05-01 |
| 2018-05-08 | 6948.60 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-04-05 | 6948.18 | 未披露 | 定期报告 | 2018-03-23 |
| 2018-03-13 | 6944.03 | 未披露 | 定期报告 | 2018-03-01 |
| 2018-03-13 | 6930.17 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of common stock (net of commissions and offering costs of $388)
Exercise of stock options and vesting of restricted stock units
Issuance of shares under employee stock purchase plan
|
2017-12-31 |
| 2017-11-01 | 6928.26 | 未披露 | 定期报告 | 2017-10-25 |
| 2017-11-01 | 6923.70 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-07 | 5846.65 | 未披露 | 定期报告 | 2017-08-01 |
| 2017-08-07 | 5843.30 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-04-28 | 5835.82 | 未披露 | 定期报告 | 2017-04-24 |
| 2017-05-08 | 5835.00 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-03-13 | 5824.87 | 未披露 | 定期报告 | 2017-03-01 |
| 2017-03-13 | 5805.03 | 未披露 |
更多>>
From December 31, 2015 to December 31, 2016
Issuance of common stock (net of commissions and offering costs of $483)
Exercise of stock options
Issuance of shares under employee stock purchase plan
|
2016-12-31 |
| 2016-11-03 | 5801.14 | 未披露 | 定期报告 | 2016-10-28 |
| 2016-11-03 | 5800.20 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-08-08 | 5795.70 | 未披露 | 定期报告 | 2016-08-03 |
| 2016-08-08 | 5793.70 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-05-09 | 5722.27 | 未披露 | 定期报告 | 2016-05-02 |
| 2016-05-09 | 5721.81 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-09 | 5720.93 | 未披露 | 定期报告 | 2016-03-01 |
| 2016-03-09 | 4178.58 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Issuance of common stock (net of commissions and offering costs of $367)
Exercise of stock options
Issuance of shares under employee stock purchase plan
|
2015-12-31 |
| 2015-11-09 | 4170.33 | 未披露 | 定期报告 | 2015-10-30 |
| 2015-11-09 | 4169.80 | 未披露 | 定期报告 | 2015-09-30 |
| 2015-08-06 | 4132.97 | 未披露 | 定期报告 | 2015-07-31 |
| 2015-08-06 | 4124.03 | 未披露 | 定期报告 | 2015-06-30 |
| 2015-04-28 | 4120.47 | 未披露 | 定期报告 | 2015-04-24 |
| 2015-04-15 | 4048.32 | 未披露 | 定期报告 | 2015-04-01 |
| 2015-04-28 | 4048.71 | 未披露 | 定期报告 | 2015-03-31 |
| 2015-03-12 | 3447.21 | 未披露 | 定期报告 | 2015-03-06 |
| 2015-03-12 | 3442.60 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Issuance of common stock (net of commissions and offering costs of $380)
Exercise of stock options
Issuance of shares under employee stock purchase plan
|
2014-12-31 |
| 2014-11-06 | 3416.32 | 未披露 | 定期报告 | 2014-10-31 |
| 2014-11-06 | 3406.33 | 未披露 | 定期报告 | 2014-09-30 |
| 2014-08-13 | 3358.35 | 未披露 | 定期报告 | 2014-08-08 |
| 2014-08-13 | 3337.17 | 未披露 | 定期报告 | 2014-06-30 |
| 2014-06-12 | 3315.47 | 未披露 | 定期报告 | 2014-05-05 |
| 2014-04-30 | 3295.53 | 未披露 | 定期报告 | 2014-04-14 |
| 2014-05-14 | 3288.52 | 未披露 | 定期报告 | 2014-03-31 |
| 2014-02-28 | 3274.98 | 未披露 | 定期报告 | 2014-02-21 |
| 2014-02-28 | 2848.89 | 未披露 |
更多>>
from December 31, 2012 to December 31, 2013
Issuance of common stock (net of commissions and offering costs of $2,849)
Exercise of stock options
Conversion of redeemable convertible preferred stock to common stock
|
2013-12-31 |
| 2013-10-23 | 2841.93 | 未披露 | 定期报告 | 2013-10-18 |
| 2013-10-23 | 2840.87 | 未披露 | 定期报告 | 2013-09-30 |
| 2013-08-01 | 2841.69 | 未披露 | 定期报告 | 2013-07-26 |
| 2013-08-01 | 2840.25 | 未披露 | 定期报告 | 2013-06-30 |
| 2013-05-31 | 2764.38 | 未披露 |
更多>>
In addition, unless otherwise indicated, all information in this prospectus gives effect to a one-for-three reverse stock split of our common stock that was effected on May 13, 2013.
|
2013-05-31 |
| 2013-05-21 | 185.07 | 6189.92 |
更多>>
from December 31, 2012 to May 14, 2013
Exercise of stock options (unaudited)
Accretion of redeemable convertible preferred stock to redemption value (unaudited)
the Company’s Board of Directors and stockholders approved a one-for-three reverse stock split of the Company’s common stock. The reverse stock split became effective on May 13, 2013.
|
2013-05-14 |
| 2013-05-13 | 186.87 | 6189.92 | 定期报告 | 2013-04-30 |
| 2013-04-26 | 555.20 | 6189.92 |
更多>>
from December 31, 2012 to March 31, 2013
Exercise of stock options (unaudited)
Accretion of redeemable convertible preferred stock to redemption value (unaudited)
|
2013-03-31 |
From March 31, 2022 to June 30, 2022
Issuance of common stock in connection with the conversion of series A convertible preferred stock
Vesting of restricted stock units
Issuance of shares of common stock in lieu of board fees
From December 31, 2021 to March 31, 2022
Issuance of common stock (net of commissions and offering costs of $507)
Vesting of restricted stock units
Issuance of shares under employee stock purchase plan
Issuance of shares of common stock in lieu of board fees
1.Common stock offered by Epizyme 56,666,667 shares.
2.The number of shares of common stock to be outstanding after this offering is based on the 106,097,528 shares of common stock outstanding as of December 31, 2021
From December 31, 2020 to December 31, 2021
Issuance of common stock (net of commissions and offering costs of $515)
Exercise of stock options and vesting of restricted stock units
Issuance of shares of common stock in lieu of board fees
Issuance of shares under employee stock purchase plan
From June 30, 2021 to September 30, 2021
Issuance of common stock (net of commissions and offering costs of $217)
Issuance of shares under employee stock purchase plan
Issuance of shares of common stock in lieu of board fees
From March 31, 2021 to June 30, 2021
Issuance of common stock (net of commissions and offering costs of $49)
Exercise of stock options and vesting of restricted stock units
Issuance of shares of common stock in lieu of board fees
From December 31, 2020 to March 31, 2021
Exercise of stock options and vesting of restricted stock units
Issuance of shares under employee stock purchase plan
Issuance of shares of common stock in lieu of board fees
From December 31, 2019 to December 31, 2020
Issuance of common stock in connection with the exercise of the Put Option (net of financing costs of $85)
Issuance of common stock in connection with the conversion of series A convertible preferred stock
Exercise of stock options and vesting of restricted stock units
Issuance of shares of common stock in lieu of board fees
Issuance of shares under employee stock purchase plan
From June 30, 2020 to September 30, 2020
Exercise of stock options and vesting of restricted stock units
Issuance of shares under employee stock purchase plan
Issuance of shares of common stock in lieu of board fees
From March 31, 2020 to June 30, 2020
Exercise of stock options and vesting of restricted stock units
Issuance of shares of common stock in lieu of board fees
From December 31, 2019 to March 31, 2020
Issuance of common stock in connection with the exercise of the put option (net of financing costs of $85)
Issuance of common stock in connection with the conversion of series A convertible preferred stock
Exercise of stock options and vesting of restricted stock units
Issuance of shares under employee stock purchase plan
Issuance of shares of common stock in lieu of board fees
from December 31, 2018 to December 31, 2019
Issuance of common stock (net of commissions and offering costs of $284)
Issuance of common stock to Royalty Pharma (net of commissions and offering costs of $304)
Exercise of stock options and vesting of restricted stock units
Issuance of shares of common stock in lieu of board fees
Issuance of shares under employee stock purchase plan
Issuance of series A convertible preferred stock, net of commissions and beneficial conversion charge
from June 30, 2019 to September 30, 2019
Exercise of stock options and vesting of restricted stock units
Issuance of shares under employee stock purchase plan
Issuance of shares of common stock in lieu of board fees
From March 31, 2019 to June 30, 2019
Exercise of stock options and vesting of restricted stock units
Issuance of shares of common stock in lieu of board fees
from December 31, 2018 to March 31, 2019
Issuance of common stock (net of commissions and offering costs of $284)
Exercise of stock options and vesting of restricted stock units
Issuance of shares under employee stock purchase plan
Issuance of Series A Convertible Preferred Stock, net of commissions and beneficial conversion charge
from December 31, 2017 to December 31, 2018
Issuance of common stock (net of commissions and offering costs of $260)
Exercise of stock options and vesting of restricted stock units
Issuance of shares under employee stock purchase plan
Stock in lieu of board fees
from December 31, 2016 to December 31, 2017
Issuance of common stock (net of commissions and offering costs of $388)
Exercise of stock options and vesting of restricted stock units
Issuance of shares under employee stock purchase plan
From December 31, 2015 to December 31, 2016
Issuance of common stock (net of commissions and offering costs of $483)
Exercise of stock options
Issuance of shares under employee stock purchase plan
from December 31, 2014 to December 31, 2015
Issuance of common stock (net of commissions and offering costs of $367)
Exercise of stock options
Issuance of shares under employee stock purchase plan
from December 31, 2013 to December 31, 2014
Issuance of common stock (net of commissions and offering costs of $380)
Exercise of stock options
Issuance of shares under employee stock purchase plan
from December 31, 2012 to December 31, 2013
Issuance of common stock (net of commissions and offering costs of $2,849)
Exercise of stock options
Conversion of redeemable convertible preferred stock to common stock
In addition, unless otherwise indicated, all information in this prospectus gives effect to a one-for-three reverse stock split of our common stock that was effected on May 13, 2013.
from December 31, 2012 to May 14, 2013
Exercise of stock options (unaudited)
Accretion of redeemable convertible preferred stock to redemption value (unaudited)
the Company’s Board of Directors and stockholders approved a one-for-three reverse stock split of the Company’s common stock. The reverse stock split became effective on May 13, 2013.
from December 31, 2012 to March 31, 2013
Exercise of stock options (unaudited)
Accretion of redeemable convertible preferred stock to redemption value (unaudited)